Investor Relations

AmpliPhi to Present New Data on Biological Activity of Nebulized Anti-Pseudomonal Bacteriophage

Results to be presented at the 38th European Cystic Fibrosis Conference

Monday, June 8, 2015 8:03 am EDT

Dateline:

SAN DIEGO & RICHMOND, Va. & LJUBLJANA, Slovenia, & SYDNEY

Public Company Information:

OTCQB:
APHB
US03211P1030

SAN DIEGO & RICHMOND, Va. & LJUBLJANA, Slovenia, & SYDNEY--(BUSINESS WIRE)--AmpliPhi BioSciences Corporation (OTCQB:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that new data on the activity of P. aeruginosa bacteriophages after exposure to nebulizer systems applicable for use in future clinical trials will be presented at the European Cystic Fibrosis Conference, taking place in Brussels, Belgium from June 10-13.

Professor Jane Davies, MB, ChB, MRCP, MRCPCH, MD, lead study investigator from the Department of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, will present these data in a poster entitled “Towards Clinical Application of Anti-Pseudomonal Bacteriophages” (#140) on June 12 at 2:00 p.m. CET.

About AmpliPhi BioSciences

AmpliPhi BioSciences Corporation (OTCQB: APHB) is a biotechnology company focused on the development and commercialization of novel bacteriophage-based antibacterial therapeutics. The Company's product development programs target infections that are often resistant to existing antibiotic treatments. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation (NYSE: XON), the U.S. Army, The Royal Brompton Clinic in London, UK and UK-based University of Leicester, to rapidly advance bacteriophage-based therapies.

For more information, visit www.ampliphibio.com.

About Bacteriophage

Bacteriophage are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophage are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defense for bacteria, contributing to antibiotic resistance. Bacteriophage are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.

Forward Looking Statements

Statements in this press release about AmpliPhi’s manufacturing capabilities and ability to manufacture pure, reproducible, high quality, cost effective human preparations, the potential use of bacteriophages to treat bacterial infections, including infections in biofilms and infections that do not respond to antibiotics, and the development of bacteriophage-based therapies are forward looking statements subject to risks and uncertainties, including without limitation the risk that the Company will not be able to successfully manufacture sufficient quantities of products to conduct clinical trials or commercialize products in a timely manner or at all, that AmpliPhi may not commence clinical trials or complete IND-enabling studies as expected, that the clinical trials will not be successful, that further development of the Company's products will require extensive and expensive nonclinical and clinical testing, may not be safe or efficacious, and may not be approved for marketing by the United States Food and Drug Administration or any foreign regulatory agency. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to AmpliPhi's business in general, see AmpliPhi's Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as amended, filed with the Securities and Exchange Commission (SEC) on April 15, 2015.

Contact:

Company and Investor Relations:
AmpliPhi BioSciences Corporation
Baxter Phillips III, +1-804-754-5442
Chief Business Officer
bfp@ampliphibio.com
or
Media relations (USA):
Lazar Partners
Danielle Lewis/Fern Lazar, + 1 212-867-1762
ampliphi@lazarpartners.com
or
Media Relations (Europe and ROW)
Instinctif Partners
Gemma Howe/Sue Charles/Daniel Gooch, +44 (0)20 7866 7905
ampliphi@instinctif.com

Business Wire InvestorHQsm